For patients with locally advanced rectal cancer (LARC), achieving a pathological complete response (pCR) after neoadjuvant chemoradiotherapy (CRT) provides them with the optimal prognosis. However, no reliable prediction model is presently available...
Response to Neoadjuvant chemotherapy (NAC) has demonstrated a high correlation to survival in locally advanced breast cancer (LABC) patients. An early prediction of responsiveness to NAC could facilitate treatment adjustments on an individual patient...
International journal of computer assisted radiology and surgery
Jun 16, 2020
PURPOSE: Neoadjuvant chemotherapy (NAC) aims to minimize the tumor size before surgery. Predicting response to NAC could reduce toxicity and delays to effective intervention. Computational analysis of dynamic contrast-enhanced magnetic resonance imag...
BACKGROUND: For breast cancer patients undergoing neoadjuvant chemotherapy (NAC), pathologic complete response (pCR; no invasive or in situ) cannot be assessed non-invasively so all patients undergo surgery. The aim of our study was to develop and va...
Journal of medical imaging and radiation oncology
May 9, 2020
INTRODUCTION: Innovative biomarkers to predict treatment response in rectal cancer would be helpful in optimizing personalized treatment approaches. In this study, we aimed to develop and validate a CT-based radiomic imaging biomarker to predict path...
Radiomic features achieve promising results in cancer diagnosis, treatment response prediction, and survival prediction. Our goal is to compare the handcrafted (explicitly designed) and deep learning (DL)-based radiomic features extracted from pre-tr...
BACKGROUND: The aim of the study was to develop a deep learning (DL) algorithm to evaluate the pathological complete response (pCR) to neoadjuvant chemotherapy in breast cancer.
In patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy (NAC), some patients achieve a complete pathologic response (pCR), some achieve a partial response, and some do not respond at all or even progress. Accurate predicti...
INTRODUCTION: Osteosarcoma is the most common malignant bone tumor before 25 years of age. Response to neoadjuvant chemotherapy determines continuation of treatment and is also a powerful prognostic factor. There are currently no reliable ways to eva...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.